Share Price, page-8947

whether the company is taken over by BP or not is irrelevant for people with these neurodevelopment disorders. They'll get the drug just as quickly whether we're taken over or not. In fact there's a greater risk is that if 2591 is part of a suite of drugs under development by a BP it will receive less priority and will take more time to commercialisation than if we do it ourselves, or licence it out to someone like Acadia. The CGT issue is completely separate from that. In fact, the ATO will probably get much higher corporate profits tax revenue from NEU if it remains in Australian hands than if it's sold off to overseas interests. Our economy, export revenue and employment of specialists will benefit a lot more by NEU remaining in Australian hands.